Middle East and Africa Allergy Immunotherapies Market Size and Competitive Analysis by 2027

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

Middle East and Africa Allergy Immunotherapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)); Allergy type (Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Country

  • Report Date : Nov 2020
  • Report Code : TIPRE00016213
  • Category : Life Sciences
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 75
Page Updated: Nov 2020

The Middle East & Africa Allergy immunotherapies market was valued at US$ 137.87 million in 2019 and is projected to reach US$ 297.62 million by 2027; it is expected to grow at a CAGR of 10.2% during the forecast period.



The increasing prevalence of allergic disorders and technological advancements in sublingual dosage formulations are the key factors fueling the allergy immunotherapies market growth.

Allergen immunotherapy is a medical treatment useful for environmental allergies, insect bite allergies, and asthma. This involves the regular administration of gradually increasing the dose of allergen extracts into the patient’s body over a certain period. The Allergy Immunotherapy market in the Middle East and Africa region is expected to exhibit the highest growth rate due to the increased incidence of allergy people in developing countries like Saudi Arabia and South Africa. In the recent report of the National Health and Nutrition Examination Survey, 54% of the population had positive test responses to one or more allergens. Allergic disorders are mostly treated with immunotherapy; thus, the growing prevalence of allergic diseases drives the growth of the market. Also, the growing unmet needs of novel targeted drugs, which are used to treat the allergic conditions, will create growth opportunities for the market players. Many companies are investing in research and development to develop targeted drugs for various allergic disorders.

The Covid-19 pandemic has harmed Middle East and Africa allergy immunotherapies market size, with small and medium scale companies struggling to sustain their businesses in the near-term future. Industry leaders are now focusing on creating new business practices to deal with crises like Covid-19 pandemic.

Middle East and Africa Allergy Immunotherapies Market Revenue and Forecast to 2027 (US$ Mn)

Middle East and Africa Allergy Immunotherapies Market Revenue and Forecast to 2027 (US$ Mn)
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

MIDDLE EAST AND AFRICA ALLERGY IMMUNOTHERAPIES MARKET SEGMENTATION

By Treatment

  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)

By Allergy Type

  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Venom Allergy
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Country

  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Company Profiles

  • HAL Allergy B.V.
  • ALK Abello A/S
  • Stallergenes Greer
  • Anergis
  • Circassia

Middle East and Africa Allergy Immunotherapies Report Scope

Report Attribute Details
Market size in 2019 US$ 137.87 Million
Market Size by 2027 US$ 297.62 Million
Global CAGR (2019 - 2027) 10.2%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Treatment
  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy
By Allergy type
  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Venom Allergy
By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Regions and Countries Covered Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • HAL Allergy B.V.
  • ALK Abello A/S
  • Stallergenes Greer
  • Anergis
  • Circassia
  • Mrinal Kerhalkar
    Manager,
    Market Research & Consulting

    Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

    Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Identifying Emerging Markets
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Boosting Operational Efficiency
    • Strategic Planning
    • Investment Justification
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Our Clients
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo